China’s ‘precision medicine’ initiative gets lift from latest genomics company funding May 2, 2017 Life Science
DelMar to Present Poster of Clinical Research with VAL-083 in Patients with Chemo-Resistant Glioblastoma (“GBM”) at ASCO Annual Meeting Apr 28, 2017 Life Science
DelMar Pharmaceuticals Collaborates with Duke University to Explore VAL-083 as a Front-Line Treatment for Glioblastoma Multiforme Apr 26, 2017 Life Science
RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA® Phase II Study for IBS-D Apr 24, 2017 Life Science
DelMar Pharmaceuticals Announces Closing Of $9,000,000 Public Offering Of Common Stock And Warrants Apr 22, 2017 Life Science
RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA® Apr 18, 2017 Life Science
DelMar Pharmaceuticals Announces Pricing Of $9,000,000 Public Offering Of Common Stock And Warrants Apr 14, 2017 Life Science
DelMar Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Warrants Apr 13, 2017 Life Science
DelMar Pharmaceuticals Provides VAL-083 Updates from the Ongoing American Association for Cancer Research (AACR) Annual Meeting Apr 6, 2017 Life Science
RedHill Biopharma Receives FDA Orphan Drug Designation for YELIVA® for the Treatment of Cholangiocarcinoma Apr 5, 2017 Life Science
RedHill Biopharma Announces Exclusive U.S. License from Entera Health for Commercial GI Product EnteraGam® Apr 5, 2017 Life Science
DelMar Pharmaceuticals Announces Abstract Presentations for the American Association for Cancer Research (AACR) Annual Meeting in April 2017 Mar 29, 2017 Life Science
Resverlogix Announces Third Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone and Provides an Update on Corporate Activities Mar 19, 2017 Life Science
Resverlogix Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office Mar 15, 2017 Life Science
DelMar Pharmaceuticals to Participate in Key Opinion Leader Luncheon on Glioblastoma Multiforme Featuring Dr. James Perry, MD Mar 3, 2017 Life Science
Resverlogix Reports Positive FDA Type B Meeting on Design Issues Relating to a Proposed Phase 2a Kidney Dialysis Trial Feb 24, 2017 Life Science
DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2017 Financial Results Feb 14, 2017 Life Science
Resverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy (FSHD) and Neurodegenerative Eye Disease Feb 14, 2017 Life Science
